Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.

Thyrocare Technologies posts Q1FY23 consolidated PAT at Rs. 21.73 Cr

The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.

Statement from Krsnaa Diagnostics on IT survey

The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma

Cipla posts Q1FY23 consolidated PAT at Rs. 686.40 Cr

he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.

Torrent Pharmaceuticals posts Q1FY23 consolidated PAT Rs. 354 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.

Cariflex breaks ground on world's largest polyisoprene latex plant in Singapore

Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments

Alniche Lifesciences celebrates 15 anniversary

The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.

GMM Pfaudler Q1FY23 consolidated PAT surges to Rs. 44.51 Cr

GMM Pfaudler has reported total income of Rs. 767.73 crores during the period ended June 30, 2022

Biocon Q1FY23 consolidated PAT falls QoQ at Rs. 144.4 Cr

Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.

Novartis India Q1FY23 PAT jumps to Rs. 52.38 Cr

Novartis India has reported total income of Rs. 147.44 crores during the period ended June 30, 2022.

Velocity Clinical Research begins European expansion with German site acquisition

Biopharma and CROs to benefit from simplified access to global research sites

Strong execution in Q2 drives full-year 2022 guidance upgrade for Sanofi

Dr Lal Path Labs Q1 FY23 consolidated PAT drops to Rs. 57.7 Cr

Dr. Lal Path Labs has reported total income of Rs. 511 crores during the period ended June 30, 2022

Ascentage Pharma and Tanner Pharma Group initiate a global innovative named Patient Program

Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.

SKYCovione will strengthen South Korea position in global COVID-19 vaccine industry, says GlobalData

This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines

AstraZeneca collaborates with – Indian Society of Nephrology to launch CKD Academy

AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.

Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr

Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.

Astec LifeSciences Q1 FY2023 consolidated PAT drops to Rs. 11.39 Cr

The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.

Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr

The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.